Open Nav

John Valliant


Fusion Pharmaceuticals Inc.

John founded Fusion and was the driving force behind an oversubscribed series A financing

($46M USD), led by Johnson & Johnson Innovation–JJDC, Inc., closing in late 2017.

Under John’s leadership, and with the support of an international syndicate of investors and a

world-class executive team, Fusion has established itself as the leading targeted alpha therapy

company by combining a high value pipeline, proprietary linker technology, and innovative

partnering and supply chain strategies.

Fusion is a clinical stage-oncology company focused on developing novel targeted alpha

therapeutics (TATs) for the treatment of chemotherapy resistant cancers. Fusion's lead

product, FPX-1434, combines the precise targeting of a human experienced antibody with

Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 to induce cancer

cell death. Fusion, which also has an exciting pipeline and internal R&D and clinical development

programs, has offices in Canada and the U.S.

This speaker's sessions: